Adverum Biotechnologies — Proxy Contest (April 2021)
65 slides from Adverum Biotechnologies's proxy contest presentation, Apr 22, 2021
Slide 1: The Case for an Improved Board at Adverum
The Case for an Improved Board at Adverum April 22, 2021 www.SaveAdverum.com
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKEN AS ADVICE O
Slide 3: Table of Contents
Table of Contents I. Introduction & Executive Summary 4 II. The Board’s Entrenchment Maneuvers 17 III. Massive Stockholder Value Destruction 30 IV. A Failure of Oversight and Governance 46 V. Sonic’s Independent Nominees 54 VI. The Path Forward 63 3
Slide 4: I. Introduction & Executive Summary
I. Introduction & Executive Summary
Slide 5: About Sonic
About Sonic Sonic Fund II, L.P. ❑ Founded in 2004 2018 ❑ Long/Short equity hedge fund focused on long-term value Year Sonic creation first invested ❑ Specialized and concentrated in biotechnology and specifically in Adverum gene therapy Lawrence Kam, General Partner ❑ Life Sciences educational backg
Slide 6: About Adverum & ADVM-022
About Adverum & ADVM-022 Adverum Biotechnologies ❑ A clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases ❑ The Company is currently advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injectio
Slide 7: There is a Huge Market for Treating Macular Degeneration
There is a Huge Market for Treating Macular Degeneration Adverum Corporate Presentation – April 2021 ❑ As Adverum itself points out, there is a massive need for better treatments for wet AMD ❑ ADVM-022 represents a vast improvement over the current standard of care, which requires repeated shots in
Slide 8: An Instructive Comparison
An Instructive Comparison Both KOD and ADVM are reporting good efficacy data but the inflammation issue is killing ADVM’s stock ❑ It is clear that the Adverum product works better since most patients never need another injection into the eye ❑ The Kodiak product has longer treatment intervals than t
Slide 9: Adverum vs. Kodiak Sciences
Adverum vs. Kodiak Sciences 1800 Kodiak Secondary @ 1600 $108.00 1400 Kodiak Secondary @ $46.00 1200 Adverum Secondary @ 1000 Adverum Starts Phase I $13.75 Trial 800 Kodiak Starts Phase I Trial Adverum Secondary @ 600 $13.00 400 200 0 Adverum Kodiak Sciences ADVERUM HAS A BETTER SOLUTION, YET ITS BU
Slide 10: Historical Engagement
HISTORICAL ENGAGEMENT ❑ Sonic has privately endeavored to assist the Company in enhancing its standing in the marketplace, identifying management and Board talent that management has been unable to attract on its own, and offering strategic input from the perspective of a major engaged stockholder ❑
Slide 11: Sonic is NOT Seeking Control
Sonic is NOT Seeking Control ❑ The Company’s attempt to paint our campaign as aimed at gaining “control” of the Board is nothing more than an artificially manufactured narrative designed to deprive stockholders of a fair say ❑ In fact, all the directors we have previously suggested and nominated to
Slide 12: Executive Summary
Executive Summary Adverum has grossly mismanaged The incumbent Board’s Board improvement is urgently the drug development process entrenchment maneuvers will lead needed to chart a better course and is doing a grave disservice to to more of the same and forward and responsibly hold stockholders dise
Slide 13: Investors Have Clearly Recognized the Company's Drug Development Failures
Investors Have Clearly Recognized the Company’s Drug Development Failures 30 Laurent Fischer Named CEO 25 Addition of three Laurent Fischer 20 mutually-chosen new Failed Presentation independent directors Leone Patterson and Equity Offering Failed Presentation 15 10 5 0 ADVERUM’S FAILURE TO ADEQUATE
Slide 14: An Unnecessary Proxy Contest and Waste of $7M of Company's Cash
An Unnecessary Proxy Contest and Waste of $7M of Company’s Cash Sonic has privately endeavored to assist the Company in enhancing its standing in the marketplace, identifying management and Board talent that management has been unable to attract on its own, and offering strategic input from the pers
Slide 15: Abusing the Corporate Machinery
Abusing the Corporate Machinery ❑ Since 2015, the gap between Adverum’s definitive proxy filing and the date of its Annual Meeting has ranged from 41 to 57 days ❑ This year, the gap is 27 days, a 52.6% shorter timeframe than in 2015 • In 2016, stockholder approval was sought for the merger of the tw
Slide 16: Our Highly Qualified Nominees
Our Highly Qualified Nominees Jean Bennett, M.D., Ph.D. Jodi Cook, Ph.D. Herbert Hughes ✓ Extensive Biotechnology and ✓ Extensive Biotechnology and ✓ Extensive Executive Leadership Gene Therapy Experience Gene Therapy Experience Experience ✓ Executive Leadership Experience ✓ Public Company Board ✓ B
Slide 17: II. The Board's Entrenchment Maneuvers
II. The Board’s Entrenchment Maneuvers
Slide 18: Engagement Timeline (1/2)
ENGAGEMENT TIMELINE (1/2) Date Event March 15, 2021 Sonic sent letters to the Board, outlining its concerns with the management and oversight of the Company and stating its intent to nominate five nominees at the upcoming Annual Meeting (the “March 15 Letters”). March 15, 2021 Kleinberg, Kaplan, Wol
Slide 19: Engagement Timeline (2/2)
ENGAGEMENT TIMELINE (2/2) Date Event March 24, 2021 Sonic sent to Peter Soparkar (“Mr. Soparkar”), Secretary of the Company, its formal nomination letter as required by the bylaws of the Company, formally nominating four of its Nominees—Jean Bennett, Jodi Cook, Bard Geesaman and Annahita Keravala. M
Slide 20: Sonic is NOT Trying to Take Control – Trying to Restore Independence
Sonic is NOT Trying to Take Control – Sonic is Trying to Restore Independence to the Board Normal Activist Control Situation: Company’s Slate vs. Activist’s Slate Board Board Board Board Board Board Board Board Board Activist Activist Activist Activist Chair CEO Chair CEO Activist Member Member Memb
Slide 21: Adverum's Merry-Go-Round of Increasing and Decreasing the Board
Adverum’s Merry-Go-Round of Increasing and Decreasing the Board ❑ On March 16, 2021, Adverum representatives tell Sonic that Rekha Hemrajani, Eric Carter, and CLASS I CLASS II CLASS III Thomas Woiwode will not be re-nominated at CURRENT BOARD COMPOSITION 2021 Annual Meeting and the Board would Rekha
Slide 22: Adverum's Chair and CEO Are Seemingly Entrenching Themselves
Adverum’s Chair and CEO Are Seemingly Entrenching Themselves ❑ Adverum will have to expand the Board to 11 seats by the end of 2021 to add the required proportion of female directors to comply with California law ❑ So even if one were to concede their argument – which Sonic does not – that any direc
Slide 23: A Hand-Picked Board – Just Look at Their Proxy
A Hand-Picked Board – Just Look at Their Proxy It is clear that Mr. Machado, with the help of Dr. Fischer, is pulling the strings to pack the Board. “In October 2020, seeking to add significant commercial expertise to the Board, Mr. Machado began the recruitment of Dawn Svoronos that led to her subs
Slide 24: Adverum's Logical Fallacy
Adverum’s Logical Fallacy Adverum Definitive Proxy Statement – April 15, 2021 Adverum Letter to Stockholders – April 15, 2021 HOW CAN ADVERUM ARGUE THAT THE INCUMBENT DIRECTORS ADDED TO THE BOARD IN 2019 IN COLLABORATION WITH SONIC ARE ALIGNED WITH SONIC, GIVEN THAT THE BOARD “UNANIMOUSLY” SUPPORTS
Slide 25: Fact vs. Fiction
Fact vs. Fiction Adverum Press Release – April 15, 2021 Sonic’s Email to Director Mark Lupher, Ph.D. – February 3, 2020 ----- Original Message ----- From: Lawrence Kam “Mr. Kam expressed his desire for Mr. To: Mark Lupher Sent: Monday, February 03, 2020 9:41 AM Chalberg to be the CEO of Adverum, Sub
Slide 26: Adverum Has Misrepresented Sonic's Suggestions Regarding Management
Adverum Has Misrepresented Sonic’s Suggestions Regarding Management Adverum claims Sonic has “relentlessly engaged” In reality, Sonic has been constructively working with Adverum since with the Board September 2019 Let’s see for ourselves if actual emails are considered relentless engagements or con
Slide 27: Sonic has Proactively Engaged with Adverum Since September 2019 (1 of 2)
Sonic has Proactively Engaged with Adverum Since September 2019 (1 of 2) From: Lawrence Kam From: Patrick Machado From: Lawrence Kam From: Lawrence Kam From: Lawrence Kam To: Patrick Machado To: Lawrence Kam To: Mark Lupher, To: Mark Lupher To: Laurent Fischer Sent: December 19, 2019 Cc: Mark Lupher
Slide 28: Sonic has Proactively Engaged with Adverum Since September 2019 (2 of 2)
Sonic has Proactively Engaged with Adverum Since September 2019 (2 of 2) From: Lawrence Kam From: Lawrence Kam From: Patrick Machado From: Lawrence Kam From: Lawrence Kam To: Laurent Fischer, Leo Kim To: Patrick Machado To: Lawrence Kam To: Patrick Machado To: Laurent Fischer Sent: September 8, 2020
Slide 29: Sonic Has Made Constructive Scientific Recommendations to Adverum
Sonic Has Made Constructive Scientific Recommendations to Adverum September 2, 2020 Letter from Mr. Kam to Mr. Fischer 29
Slide 30: III. Massive Stockholder Value Destruction
III. Massive Stockholder Value Destruction
Slide 31: Adverum is Not Behaving Like Other Biotech Companies
Adverum is Not Behaving Like Other Biotech Companies Adverum under CEO Adverum under CEO Typical Biotech Stock Leone Patterson Laurent Fischer Remediate What makes stock Present Good News presentation of N/A go UP from clinical trial “Good News” What makes stock Present Bad News Present “Good News”
Slide 32: Adverum Stock Performance Over Time
Adverum Stock Performance Over Time 30 Laurent Fischer Named CEO 25 20 Laurent Fischer Failed Presentation Sonic Board Changes Leone Patterson and Equity Offering Failed Presentation 15 10 5 0 As of market close on April 20, 2021 32
Slide 33: Adverum's Abysmal TSR
Adverum’s Abysmal TSR TSR Since Laurent Fischer was named CEO of Adverum 1-Year TSR 60.00% 48.41% 110.00% 91.69% 36.62% 40.00% 90.00% 16.93% 70.00% 20.00% 48.91% 50.00% 0.00% 30.00% 20.78% -20.00% 10.00% -40.00% -10.00% -60.00% -30.00% -80.00% -62.36% -50.00% -36.56% Adverum Ocular Drug Peers* Nasda
Slide 34: The Board's Failed Oversight
The Board’s Failed Oversight The current Board has proven itself incapable of oversight by: ❑ Not preventing botched presentations ❑ Not remediating damage already done ❑ Not controlling compensation THE BOARD HAS HAD TWO YEARS TO SHOW WHAT THEY COULD DELIVER FOR STOCKHOLDERS – THEY HAVE FAILED 34
Slide 35: Q2 2020 Earnings Call
Q2 2020 Earnings Call On the Q2 2020 earnings call, there was question after question regarding inflammation and steroid drops. The Company had clearly not assuaged concerns about the issue. 35
Slide 36: Scientific Mismanagement
Scientific Mismanagement Adverum reported the promising results of its ADVM-022 trial for Fast-forward nearly a year: Laurent The FDA refused to approve Allergan’s Abicipar the first time. Rather than Fischer, who sits on two other boards pegol, noting that “the rate of intraocular presenting a stra
Slide 37: A Better Approach is Needed
A Better Approach is Needed 1 2 3 Better safety = Adverum must Non-human primates have better valuation immediately investigate proven to be a predictive suitable prophylaxis to model and experiments improve safety should be performed on Goal should be to exhaustively ascertain them to determine the
Slide 38: Botched Investor Communications and Capital Allocation
Botched Investor Communications and Capital Allocation The Company’s current leadership has not fared any better in the world of investor relations than it has in the scientific development process. Consider the following: Contrary to the time- tested industry practice of presenting While the Compan
Slide 39: SG&A / Cash Burn
SG&A / Cash Burn ❑ In January 2021, the Company announced an investment of $80 million in the development of a 174,000 square foot manufacturing facility that will require 200 additional jobs on the payroll ❑ General and administrative expenses increased 81% between 2018 and 20201 ❑ In order to rais
Slide 40: An Instructive Comparison
An Instructive Comparison Both KOD and ADVM are reporting good efficacy data but the inflammation issue is killing ADVM’s stock ❑ It is clear that the Adverum product works better since most patients never need another injection into the eye ❑ The Kodiak product has longer treatment intervals than t
Slide 41: Adverum vs. Kodiak Sciences
Adverum vs. Kodiak Sciences 1800 Kodiak Secondary @ 1600 $108.00 1400 Kodiak Secondary @ 1200 $46.00 Adverum Secondary @ 1000 Adverum Starts Phase I $13.75 Trial 800 Kodiak Starts Phase I Trial Adverum Secondary @ 600 $13.00 400 200 0 Adverum Kodiak Sciences EACH $100 INVESTED ON OCTOBER 1, 2018, WO
Slide 42: KSI-301 Phase I results are "Good"
KSI-301 Phase I results are “Good” 42
Slide 43: ADVM-022 Phase I results are "Better"
ADVM-022 Phase I results are “Better” 43
Slide 44: What Wall Street is Saying (1 of 2)
What Wall Street is Saying (1 of 2) Over the past week, the While we "get" the 3x1011dose, We initiate coverage of ADVM Obviously in a Phase I, there are Assuming ADVM-022 is discussion around any we were surprised by the lowest with a Neutral rating and $13 lots of learnings that come with eventual
Slide 45: What Wall Street is Saying (2 of 2)
What Wall Street is Saying (2 of 2) So the biggest controversy on Wall However, given observed Topical steroids represent the mildest Using the visual acuity, like, to me it We believe the ADVM investment Street today with ADVM-022 is inflammation out to week 40 and treatment option available to loo
Slide 46: IV. A Failure of Oversight and Governance
IV. A Failure of Oversight and Governance
Slide 47: Overview of the Board's Failures
Overview of the Board’s Failures Interconnected Board Nominees who lack basic members who lack relevant (and essential) independence skillsets Egregious executive Skyrocketing director compensation and non- compensation even existent oversight of CEO during pandemic THE BOARD LACKS THE EXPERIENCE AN
Slide 48: Adverum Acknowledges its Board Members are Connected…
Adverum Acknowledges its Board Members are Connected… In Adverum’s latest proxy, it tries to convince its stockholders that Dawn Svoronos, Reed V. Tuckson, M.D., Thomas Woiwode, Ph.D. are “independent” In making these determinations, our Board considered the current and prior relationships that each
Slide 49: …But Promises Stockholders Their Tangled Web Is Not an Issue
…But Promises Stockholders Their Tangled Web Is Not an Issue Reed V. Tuckson, M.D. Board Member Stockholders are entitled to question his true Stockholders are entitled to independence from Dr. Fischer, regardless of question her true independence Patrick whether he technically meets a Nasdaq from M
Slide 50: Executive Compensation is Excessive Compared to Results and Peers
Executive Compensation is Excessive Compared to Company’s Results and Peers Sonic believes that the Company’s overall compensation arrangements are unjustifiably generous ❑ Stockholders will recall that twice within ❑ Against this backdrop, stockholders ❑ As noted by the San Francisco Business the l
Slide 51: Skyrocketing Director Compensation
Skyrocketing Director Compensation Non-employee director compensation has increased from $1.3M during 2018 to a staggering $6.2M in 2020! You may consider that a big increase in a very short time, especially when measured against performance and the steps many corporations have taken to moderate con
Slide 52: The Company's Nominees Do Not Measure Up
The Company’s Nominees Do Not Measure Up Dawn Svoronos Reed V. Tuckson, M.D. Thomas Woiwode, Ph.D. Board Member Board Member Board Member × No gene therapy experience × No gene therapy experience × He is a representative of Versant Ventures IV, a venture fund. Versant × No ophthalmology experience ×
Slide 53: A Lack of Relevant Experience
A Lack of Relevant Experience Drug Gene Therapy Ophthalmology Truly Development Experience? Experience? Independent? Experience? Dawn Svoronos NO NO NO NO Reed V. Tuckson, M.D. NO NO NO NO Thomas Woiwode, Ph.D. NO NO 53
Slide 54: V. Sonic's Independent Nominees
V. Sonic’s Independent Nominees
Slide 55: Our Highly Qualified Nominees
Our Highly Qualified Nominees Jean Bennett, M.D., Ph.D. Jodi Cook, Ph.D. Herbert Hughes ✓ Extensive Biotechnology and ✓ Extensive Biotechnology and ✓ Extensive Executive Leadership Gene Therapy Experience Gene Therapy Experience Experience ✓ Executive Leadership Experience ✓ Public Company Board ✓ B
Slide 56: Nominees Possess Qualifications Across Various Relevant Areas
Nominees Possess Qualifications Across Various Relevant Areas to Adverum’s Business Executive Leadership Drug Gene Therapy Ophthalmology Truly and/or Capital Development Experience? Experience? Independent? Allocation Experience? Experience? Jean Bennett, M.D., Ph.D. YES YES YES YES Jodi Cook, Ph.D.
Slide 57: Jean Bennett, MD, PhD
Jean Bennett, MD, PhD ❑ Dr. Bennett is Professor of Ophthalmology and Cell and Developmental Biology and a Senior Investigator in the F. M. Kirby Center for Molecular Ophthalmology at the University of Pennsylvania School of Medicine ❑ She is a Senior Investigator at the Center for Cellular and Mole
Slide 58: Jean Bennett, MD, PhD
Jean Bennett, MD, PhD Click this link to watch video: https://www.smithsonianmag.com/sponsored/dr-jean- bennett-dr-katherine-high-win-1-million-sanford- lorraine-cross-award-180971275/ 58
Slide 59: Jodi Cook, PhD
Jodi Cook, PhD ❑ Dr. Cook has extensive experience in gene therapy development from initial research development through commercialization ❑ She served as Head of Gene Therapy Strategy at PTC Therapeutics, Inc from 2018 until 2020. Prior to joining PTC Therapeutics, she was one of the founding membe
Slide 60: Jodi Cook, PhD
Jodi Cook, PhD Jodi has been serving as a director of Fennec Pharmaceuticals for the last two years. During her tenure we have worked closely in several important areas such as business development and evaluation of various in-licensing gene therapy programs. What’s impressed me the most is her quic
Slide 61: Herbert Hughes
Herbert Hughes ❑ Mr. Hughes has over 30 years of experience in the financial industry as an advisor and leader of a diverse range of businesses ❑ Since March 2017, Mr. Hughes has been the Chief Financial Officer of Wormhole Labs, a technology company in augmented reality and gaming industry and serv
Slide 62: Herbert Hughes
Since joining the board, Herb’s native intelligence and tremendous experience across a broad spectrum of business endeavors has proven to be invaluable. With Herb’s help we launched ‘our new flagship product in 2019 quickly started to grow the top line. In 2019 sales eclipsed $900,000 and in 2020, w
Slide 63: VII. The Path Forward
VII. The Path Forward
Slide 64: Adverum's Opportunity
Adverum’s Opportunity Develop a Seriously prudent fiscal Improved Board address the plan to minimize assesses the long-ignored the damage Restore current situation issue of ocular caused by investor at Adverum and inflammation in undisciplined trust and sets strategic a scientifically capital raises
Slide 65: Contacts
Contacts Investors John Ferguson Saratoga Proxy Consulting LLC (212) 257-1311 [email protected] Media Joe Germani / Sarah Braunstein Sloane & Company [email protected] / [email protected]